X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Dr. Pascal Piedbois Joins One2Treat To Boost Clinical Trials

Content Team by Content Team
16th July 2024
in Press Statements
Dr. Pascal Piedbois Joins One2Treat To Boost Clinical Trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In Brussels, July 9th, 2024, Dr. Pascal Piedbois assumed a pivotal role at One2Treat, tasked with ensuring their offerings meet the rigorous standards of both patients and clinical sponsors. Founded by Marc Buyse, One2Treat is pioneering an innovative approach aimed at reducing trial sample sizes and accelerating patient access to new treatments. Their software integrates multiple clinical outcomes crucial to patients right from the study design phase, employing robust statistical methodologies. Dr. Piedbois, a distinguished figure in Medical Oncology with over 30 years of experience, brings a wealth of expertise from academia and industry, including leadership roles at Paris University and prominent pharmaceutical companies like AstraZeneca and Bristol Myers Squibb.

Sebastien Coppe, CEO of One2Treat, underscores Pascal’s strategic role, emphasizing the industry’s need to integrate diverse patient-relevant outcomes into holistic treatment assessments. He highlights that current clinical studies often underutilize valuable data by focusing narrowly on primary endpoints, failing to capture the full impact of treatments on patients. Pascal’s leadership is expected to drive significant transformations in clinical trial design, aligning studies more closely with patient priorities such as quality of life.

Dr. Pascal Piedbois stresses the importance of early engagement with stakeholders—patients, sponsors, regulators, and payers—in shaping clinical trial designs. This collaborative approach, he argues, allows for better alignment on primary endpoints early in the study process, enhancing trial efficiency and speeding up the path to market for new therapies. His goal is to ensure that clinical trials accurately reflect what matters most to patients, thereby improving treatment outcomes and patient satisfaction.

Marc Buyse, Founder of One2Treat, expresses his enthusiasm for Pascal’s appointment, citing their longstanding collaboration and Pascal’s deep medical expertise as catalysts for advancing a patient-centric agenda in clinical research. He believes Pascal’s insights will accelerate the adoption of a multi-dimensional approach that resonates strongly with medical leaders and enhances the overall efficacy of treatments brought to market.

Dr. Pascal Piedbois further elaborates on One2Treat’s broader impact, emphasizing their role in fostering a more transparent and efficient transition from drug development to market access. By employing rigorous quantitative methods to assess treatment effects comprehensively, One2Treat aims to bridge the gap between clinical research and health technology assessments, offering robust benefit-risk evaluations that align closely with patient needs.

About One2Treat:

One2Treat collaborates closely with biopharmaceutical firms, providing transformative insights into clinical trial design, analysis, and market access evaluations to support holistic treatment decisions. Driven by a commitment to patient-centricity, One2Treat harnesses advanced statistical methodologies and software solutions to integrate diverse efficacy and safety outcomes into unified measures. This innovation enables the estimation of Net Treatment Benefits aligned with patient preferences, heralding a new era of personalized healthcare. One2Treat empowers sponsors to optimize registration trials by incorporating multiple patient-relevant outcomes into primary analyses, resulting in smaller, more targeted trials and accelerated R&D timelines. Additionally, their comprehensive benefit-risk assessments and patient-centric analyses facilitate smoother market access, aligning with evolving healthcare needs. As initiatives to prioritize patient preferences in treatment development gain momentum, One2Treat’s pioneering trial designs are poised to set a new industry standard.

For more information on One2Treat’s innovative solutions and their transformative impact on clinical trial design and market access, visit www.one2treat.com and join the movement towards patient-centered healthcare.

Previous Post

Keeping Pharma Packaging Safe While Pushing Sustainability

Next Post

$383.1B M&A Strategies By Biopharma For Patent Expirations

Related Posts

Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Press Statements

APM Steam Highlights Comprehensive HVAC Insulation Services for Biopharmaceutical and Pharmaceutical Facilities

19th April 2025
Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Drug Development

Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

4th March 2025
Next Post

$383.1B M&A Strategies By Biopharma For Patent Expirations

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In